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Objectives This study sought to evaluate the effects of fractional ﬂow reserve (FFR) measurement
variability on FFR-guided treatment strategy.
Background Current appropriateness guidelines recommend the utilization of FFR to guide cor-
onary revascularization based on a ﬁxed cut-off of 0.8. This rigid approach does not take into
account the intrinsic biological variability of a single FFR result and the clinical judgment of ex-
perienced interventionists.
Methods FFR reproducibility data from the landmark Deferral Versus Performance of PTCA in Pa-
tients Without Documented Ischemia (DEFER) trial was analyzed (two repeated FFR measurements in
the same lesion, 10 min apart) and the standard deviation of the difference (SDD) between repeated
measurements was calculated. The measurement certainty (probability that the FFR-guided revascu-
larization strategy will not change if the test is repeated 10 min later) was subsequently established
across the whole range of FFR values, from 0.2 to 1.
Results Outside the [0.75 to 0.85] FFR range, measurement certainty of a single FFR result is 95%.
However, closer to its cut-off, certainty falls to less than 80% within 0.77 to 0.83, reaching a nadir of
50% around 0.8. In clinical practice, that means that each time a single FFR value falls between 0.75
and 0.85, there is a chance that the FFR-derived revascularization recommendation will change if the
measurement is repeated 10 min later, with this chance increasing the closer the FFR result is to 0.8.
Conclusions A measurement FFR gray-zone is found between 0.75 and 0.85]. Therefore, clinicians
should make revascularization decisions based on broadened clinical judgment when a single FFR
result falls within this uncertainty zone, particularly between 0.77 and 0.83, when measurement cer-
tainty falls to less than 80%. (J Am Coll Cardiol Intv 2013;6:222–5) © 2013 by the American College
of Cardiology Foundation
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223Over the last 20 years, the development of fractional flow
reserve (FFR) has promoted a major shift in paradigm in
assessing coronary stenosis severity in the cardiac catheter-
ization laboratory. Supported by clinical data (1–4), invasive
coronary physiology has been shown to improve patient
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outcomes by selecting patients for percutaneous coronary
interventions. At times of increased scientific (5) and public
(6) concerns about the appropriateness of coronary revascu-
larization, it is essential that the behavior of FFR is
discussed and clearly understood, to focus its application on
patients in whom measurements can be interpreted confi-
dently.
The idea of making a strict dichotomous revascularization
decision based on a fixed FFR cutoff with nearly absolute
diagnostic power was initially received with some skepti-
cism. However, it was subsequently accepted by most
cardiologists following demonstration of how physiological
stenosis assessment can overcome the limitations of a purely
anatomical angiographic approach and improve patient
outcomes. This has led to the incorporation of FFR into
coronary revascularization guidelines, which currently rec-
ommend its clinical use based on a fixed 0.8 cutoff (7–9).
But application of a rigid dichotomy may neglect important
physiological aspects of FFR, which have implications for
its clinical interpretation.
First, it should be remembered that the current evidence
on the value of FFR as a clinical decision tool is based on
studies that have used 2 different FFR cutoff values. The
DEFER (Deferral Versus Performance of PTCA in Pa-
tients Without Documented Ischemia) trial (1) demon-
strated the safety of a deferral strategy in stenoses with an
FFR 0.75, whereas the FAME (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation) (3) and
FAME II (Fractional Flow Reserve Versus Angiography for
Multivessel Evaluation 2) (4) studies used an 0.80 FFR
cutoff to investigate its value in guiding angioplasty. This
different choice of dichotomous cutoffs has its origin in early
validation studies, which demonstrated that an FFR 0.75
has 100% specificity to identify stenoses with inducible
ischemia in noninvasive tests, whereas an FFR of0.80 has
a sensitivity of more than 90% to exclude stenoses that
generate myocardial ischemia (10). Because both studies
yielded positive results, the most reasonable explanation is
that the main determinant of improved patient outcome in
the physiology-guided arms was the substitution of angiogra-
phy by FFR in the decision-making process, not the strict
application of either 0.75 or 0.80 FFR cutoffs. Yet, in the
post-FAME era, this diagnostic FFR gray zone is not currently
incorporated in clinical guidelines (8).Second, the DEFER-FAME gray zone (0.75 to 0.80)
does not take into account the intrinsic variability of FFR
measurements, which is important to bear in mind when
mandating a strict 0.8 cutoff to guide clinical decisions. For
instance, the current approach implies that a difference in
FFR as low as 0.01 is enough to mandate a physician to
intervene on 1 lesion and forbid a physician from interven-
ing on another. This observation is of particular importance
in the context of the current recommendations in clinical
practice guidelines, which is the use of FFR in patients with
angiographic intermediate coronary lesions of unclear phys-
iological significance (7–9). In contrast to early validation
studies of FFR (11–13), which were designed to evaluate
the performance of the index across a broad spectrum of
coronary stenoses, clinical populations are formed predom-
inantly by physiologically intermediate lesions with uni-
modally distributed FFR values that straddle the treatment
threshold, and a median FFR close to 0.80 (14,15). There-
fore, small variations in FFR results could potentially
influence clinical decisions in such populations.
To investigate the effects of FFR intrinsic variability on
treatment decisions in this clinically relevant zone, we
calculated how much the test-retest variability in FFR
measurements could affect the certainty of its results, by
analyzing the landmark FFR re-
producibility data from DEFER
(2 repeated FFR measurements,
10 min apart) using a cutoff of
0.80 (1) (Fig. 1A).
We found that, at the ex-
tremes of the disease spectrum, the diagnostic agreement
between repeated FFR measurements is 100%. Every time
cardiologists face a single FFR measurement of 0.75 or
0.85, they can be confident that stenosis classification (and
therefore revascularization strategy) is very unlikely to
change if FFR is repeated.
Within the region of physiologically intermediate values
(0.75 to 0.85), however, the agreement between repeated
FFR measurements falls, reaching a nadir of approximately
50% around its 0.80 established clinical cutpoint. In prac-
tice, this means that when repeating a measurement that is
within 0.01 of the cutoff, the chance of the repeated measure
being on the same side of the cutoff is only about a one-half.
The further away a single FFR value falls from the 0.80
cutoff, the greater the certainty that the recommended
treatment strategy will not be reversed when the test is
repeated. Outside the 0.77 to 0.83 range, measurement
certainty is approximately 80% and outside the 0.76 to 0.84
range, it is approximately 90%. Measurement certainty only
reaches 95% when FFR falls outside the 0.75 to 0.85 range
(Fig. 1B). This measurement uncertainty creates a second
type of FFR gray zone—a measurement gray zone—which
has several important implications, both to the interpretation
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Test-retest reproducibility of 2 repeated measurements of fractional ﬂow reserve (FFR) taken 10 min apart is shown as a scatter plot (A, gray dashed envelope demarcates 99%
of the data points from 0.5 to 1 and dotted lines show the 0.8 cutoffs). The classiﬁcation certainty of a single FFR measurement is presented for FFR values from 0.70 to 0.90 (B,
right vertical axis). Outside the 0.75 to 0.85 range, measurement certainty is higher than 95%. However, closer to its cutpoint, this certainty falls, reaching a nadir of approxi-
mately 50% around 0.8. In clinical practice, that means each time a single FFR value falls between 0.75 and 0.85, there is a chance that the dichotomous classiﬁcation of a steno-
sis (and therefore the FFR-guided revascularization decision) will change if the test is repeated 10 min later. Within 0.77 to 0.83 this measurement certainty falls to 80%. The
FFR diagnostic gray zone (0.75 to 0.85) is also displayed in B for comparison. FFR reproducibility data are from the landmark study DEFER (1) and data were obtained and digi-
tized, from Kern et al. (7). Classiﬁcation certainty (B, right vertical axis) was calculated using the standard formula:
112ex0.800.032 2
With x representing each FFR value. Constant e is the base of the natural logarithm and equals 2.718. 0.8 is the currently established cutoff for FFR and 0.032 is the standard
deviation of the difference (SDD) between repeated FFR measurements, obtained from the digitized DEFER (Deferral Versus Performance of PTCA in Patients Without Docu-
mented Ischemia) reproducibility data. As this analysis was performed using the SDD of the overall population, it could be applied to any FFR cutoff. The chosen FFR cutoff of
0.8 follows current recommendations from clinical guidelines (1) and is in line with the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) (3) and
FAME II (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2) trials (4).
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225practice. The causes for this variability are multifactorial and
include the variable response of the microcirculation to aden-
osine (16,17), the systemic vasodilator effects of adenosine
influencing aortic blood pressure (18,19), and a possible direct
effect of adenosine on myocardial function (20).
Clinicians interpreting the appropriateness criteria for
FFR-guided revascularization should be aware of the con-
sequence of natural biological variability of FFR on diag-
nostic classification of stenoses (Fig. 1). We suggest that
when FFR is 0.75 or 0.85, they can use a strict
dichotomous approach based solely on the FFR result,
confident that a repeat FFR will recommend the same
strategy in 95% of occasions. The lower limit (FFR 
0.75) coincides with the initially proposed cutoff from early
validation studies and the value above which the safety to
defer revascularization has been demonstrated in DEFER.
For patients with FFR between 0.75 and 0.85, however, a
repeat FFR might allocate the patient to the opposite
treatment category, with the chance of change in strategy
increasing as FFR approximates to 0.80. Between 0.77 and
0.83, the chance of this happening is as high as 1 in every 5
patients (20%).
In our view, therefore, it would be rational for clinicians
to make revascularization decisions based on broadened
clinical judgment when FFR values fall in this 0.75 to 0.85
biological variability zone, particularly between 0.77 and
0.83. Within this range, it would be particularly relevant to
use all available information (including other perfusion
imaging modalities, considering anatomical features and
risk-benefit profile) to deliver safe and suitable care for
individual patients.
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